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Objectives: This study analyzed survival with respect to lymph node involve-
ment to develop a new staging system for patients with esophageal cancer
that accurately reflects prognosis. Methods: The records of patients under-
going resection of primary esophageal cancer from 1989 to 1993 were
reviewed. The data collected included patient age and sex, tumor histologic
characteristics and location, the use of preoperative or postoperative
radiation and chemotherapy, the type of resection, the depth of tumor
invasion, the number and location of benign and malignant lymph nodes in
the resected specimen, the disease status at last follow-up, and the first site
of relapse. With an anatomically specific lymph node map, tumors desig-
nated in the current American Joint Committee on Cancer system as M1
because of extensive lymph node metastases were reclassified as N2,
reserving the M1 category for visceral metastases. Survival was analyzed by
the Kaplan-Meier method, and prognostic factors were assessed by log-
rank and Cox regression analyses. Results: There were 216 patients (159
men, 57 women) with a median age of 63.5 years. Adenocarcinoma of the
distal esophagus or gastroesophageal junction was the most common tumor
(127 patients, 59%) and Ivor Lewis esophagogastrectomy was the most
frequently performed operation. Both lymph node location (N1 versus N2)
and number (0 vs 1 to 3 vs 4 or more) significantly influenced survival.
Conclusions: A new staging system that adds an N2 M0 descriptor and
reclassifies stage groupings reflects prognosis more accurately than does
the current American Joint Committee on Cancer staging system. The
number of positive lymph nodes is also an important stratification factor.
(J Thorac Cardiovasc Surg 1998;115:660-70)
The current American Joint Committee on Cancer(AJCC)1 staging system for carcinoma of the
esophagus is TNM based. T (1 through 4) represents
progressive invasion of the tumor into the esopha-
geal wall, N reflects the presence (N1) or absence
(N0) of regional lymph node metastasis, and M
designates the presence (M1) or absence (M0) of
distant metastasis. The M1 category includes both
visceral organ metastasis and lymph node metastasis
beyond the nodes that are considered “regional.”
The adequacy of the current staging system has
been questioned for several reasons. First, it does
not fully consider tumors located at the gastro-
esophageal junction. Second, it includes only gen-
eral anatomic descriptions of which lymph nodes are
“regional” and which represent more extensive
nodal disease. Third, by considering lymph node
involvement outside of the regional nodes to be M1,
it classifies such tumors as stage IV and categorically
unresectable. Finally, it does not stratify according
to the number of metastatic lymph nodes, a factor
thought to be important for predicting survival of
patients undergoing resection for esophageal carci-
noma.
The perceived inadequacies of the current staging
system prompted us to review our experience with
patients undergoing surgical resection of primary
esophageal cancer. The objectives of this study were
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to classify lymph node involvement according to an
anatomically specific map, to analyze survival with
respect to the location and number of involved
lymph nodes, and to develop a staging classification
that accurately reflects prognosis in patients with
esophageal cancer.
Methods
The records of all patients undergoing surgical resec-
tion for primary esophageal carcinoma on the Thoracic
Service at Memorial Sloan-Kettering Cancer Center from
1989 to 1993 were reviewed. This allowed a minimum
follow-up of 3 years. Patients were excluded from analysis
if adequate follow-up information could not be obtained
by physician visit or telephone contact with the patient,
family, or primary physician. The data collected included
patient age and sex, tumor histologic characteristics and
location, the use of preoperative or postoperative radia-
tion and chemotherapy, the type of resection, the depth of
tumor invasion (T descriptor), the number and location of
benign and malignant lymph nodes in the resected speci-
men, the disease status at last follow-up, and when
appropriate the first site of relapse.
The T descriptors used were those defined by the
current AJCC staging system.1 N and M status were also
first designated according to this system, with positive
regional lymph nodes classified as N1 M0 and positive
lymph nodes extending beyond the regional area classified
as N1 M1. The process of classifying regional lymph nodes
was done by systematic review of operative summaries and
pathology reports, applying a proposed lymph node map-
ping system (Fig. 1) that provides a number for each
lymph node group by anatomic location.2 This map has
also been used in recent clinical trials examining the
treatment of resectable esophageal carcinoma. As in the
AJCC staging system, any patient with visceral metastasis
was also classified as having M1 disease. For the purposes
of a “revised” staging system, patients who had M1 disease
because of positive lymph nodes were reclassified as
having N2 M0 rather than N1 M1 disease (Table I). The
revised staging system allowed separate analysis of sur-
vival in this cohort of patients with more extensive nodal
disease but without visceral metastasis.
Overall survival was calculated from the date of oper-
ation and described with the product limit method of
Kaplan and Meier.3 Overall and disease-free survivals
were compared across the levels of prognostic factors with
the log-rank test.4 Multivariate analyses were performed
by Cox regression. All statistical tests were two-sided.
Results
During the 5-year period from January 1989
through December 1993, 233 patients underwent
esophagectomy. Follow-up information until death
or for a minimum of 3 years was available for 216
patients. These patients, 159 men and 57 women
with a median age of 63.5 years (range 31 to 85
years), form the basis of this analysis. The histologic
characteristics and anatomic locations of the pri-
mary tumors are shown in Table II. Most patients
(59%) had adenocarcinomas in the distal third of
the esophagus or at the gastroesophageal junction.
The types of operations performed and the frequen-
cies of preoperative and postoperative adjuvant
therapies are also shown in Table II. Ivor Lewis
esophagogastrectomy was the most frequently used
procedure (70% of patients). Thirty-two patients
(15%) received preoperative treatment, and 28 pa-
tients (13%) received adjuvant therapy. A total of
167 patients (77%) did not receive any treatment
other than esophagectomy. This series thus largely
reflects the outcome of patients treated by surgical
resection alone.
At last follow-up, 76 patients remained free of
disease. Information about the initial site of relapse
was not available for 21 patients who either had died
of disease or were alive with recurrent cancer. The
sites of first relapse in the remaining 119 cases are
shown in Table III. Distant metastases were the
most common initial sites of recurrent disease,
occurring in approximately 40% of patients. Local
and regional recurrences were equally frequent,
seen in 16% to 21% of patients with recurrence.
Tumor histologic characteristics did not influence
the first site of recurrence.
The overall survival curves by TNM status are
shown in Fig. 2 (A). The revised TNM classification
is shown in parentheses. Tumors designated as N1
M1 in the current AJCC system because of lymph
node metastasis beyond the regional nodes would be
classified as N2 M0 in the revised staging system.
There were no significant differences in overall
survival between T1 N0 M0 and T2 N0 M0 tumors
(p 5 0.27) or between T3 N0 M0 and T1 through T3
N1 M0 tumors (p 5 0.68). However, patients with
T1 through T2 N0 M0 tumors had a significantly
better survival than did patients with T3 N0 M0 and
T1 through T3 N1 M0 tumors (p , 0.01). In turn,
these patients had a better survival than did patients
with N2 M0 tumors (p , 0.001). The number of T1
through T2 N2 M0 tumors was too small (n 5 10) to
permit a comparison with T3 N2 M0 tumors. When
considered alone, the survival of patients with T3 N1
M0 tumors was significantly better than that of
patients with any N2 M0 tumor (p 5 0.006). The six
patients who had T4 tumors appeared to have the
worst survival, although these results must be inter-
preted with caution because of the small number of
patients in this category. It thus appears that TN
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Fig. 1. Lymph node mapping system for esophageal cancer. RUL, Right upper lobe; LUL, left upper lobe.
Stations 11 (interlobar), 12 (lobar), 13 (segmental), and 14 (subsegmental) are intrapulmonary nodes and
have been excluded. (From Casson AG, Rusch VW, Inculet RI, Ginsberg RJ, Zankowicz N, Rosenberg JC,
et al. Lymph node mapping for resectable carcinoma of the esophagus: a guide for thoracic surgeons.
Princeton (NJ): Bristol-Myers Oncology Division; 1992. Reproduced with permission.)
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status designates four groups of patients with dis-
tinctly different prognoses (Fig. 2, B).
The differences in overall survival are reflected in
the median survivals shown in Table IV and in the
disease-free survival curves shown in Fig. 3 (A). The
apparently large differences in disease-free survival
between T1 through T2 N1 M0 and T3 N0 through
N1 M0 tumors, and those between T1 through T2
N2 M0 and T3 N2 M0 tumors, must be viewed
cautiously because the small number of patients in
some of these TN subsets does not permit statisti-
cally valid comparisons (Fig. 3, B).
Overall survival was also analyzed according to
the number of positive lymph nodes, irrespective of
node location. Data concerning the total number of
lymph nodes sampled were not available for 21
patients operated on during the first 2 years of this
series, when such information was not always care-
fully noted in pathology reports. For the remaining
195 patients, the median number of lymph nodes
sampled was 17 (range 1 to 57 nodes). Correspond-
Table I. Definitions of N1 versus N2 lymph node stations used in defining TNM status for the revised staging
system for esophageal carcinoma
Tumor location N1 lymph nodes N2 lymph nodes
Cervical Levels 1, 2 All other involved nodes beyond N1
Thoracic, upper third Levels 1, 2, 3, 4, 7, 10
Thoracic, middle third Levels 2, 3, 4, 7, 8, 9, 10
Thoracic, lower third Levels 7, 8, 9, 11, 15, 16
Gastroesophageal junction Levels 9, 15, 16, 17, 18, 19, 20
Table II. Clinical characteristics of 216 patients with esophageal carcinoma
No. %
Tumor histology Adenocarcinoma 127 59
Squamous cell carcinoma 84 39
Other 5 2
Tumor location Cervical 2 0.9
Thoracic, upper third 3 1.4
Thoracic, middle third 52 24
Thoracic, lower third 59 27
Gastroesophageal junction 98 45
Multifocal 2 0.9
Type of operation Bypass, no resection 1 0.4
Transhiatal 45 21
Ivor Lewis 150 70
Left thoracotomy 7 3
Left thoracotomy and neck
incision
3 1.3
Right thoracotomy and neck
and abdominal incisions
9 4
Preoperative treatment Radiation 4 1.9
Chemotherapy 21 10
Radiation and chemotherapy 7 3
None 184 85
Adjuvant therapy Radiation 13 6
Chemotherapy 10 5
Radiation and chemotherapy 5 2
None 188 87








Local 14 (19%) 7 (16%) 22
Regional 14 (19%) 12 (21%) 26
Distant 35 (48%) 17 (38%) 53
Local and regional 5 5 10
Local and distant 2 2 4
Regional and distant 3 1 4
Total 73 44 119
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Fig. 2. A, Overall survival according to TNM stage. The revised staging system is noted in parentheses.
B, Overall survival according to the newly proposed stage groupings with the revised TNM system. Table
V describes stage groupings. Stage IV (T4, any N, M0 and any T, any N, M1) is not depicted.
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ing to the overall survival curves for T1 through T2
N0 M0 tumors, patients who had no positive nodes
had a significantly better survival rate than did any
other group (Fig. 4, A). There was no significant
difference in overall survival among the patients who
had one, two, or three positive nodes (p 5 0.54), but
there was a significant difference in survival between
this overall group and patients who had four or
more positive nodes (p , 0.001). Three groups of
patients with distinctly different prognoses could
thus be distinguished from this analysis: patients
without positive nodes, patients with one to three
positive nodes, and patients with four or more
positive nodes (Fig. 4, B). The number of positive
lymph nodes did not correlate with N1 versus N2
nodal status, indicating that this is a separate prog-
nostic indicator. In a multivariate analysis, both
TNM status and the number of positive nodes had a
statistically significant impact on overall survival in
patients with four or more positive nodes (hazard
ratio 1.77); however, a score of one to three positive
nodes was not an independent predictor of a worse
survival (hazard ratio 0.93).
Discussion
The purpose of a cancer staging system is to
predict survival on the basis of the anatomic extent
of tumor. This information can then be used to
direct therapy. For a staging system to be accurate
and clinically useful, it must be based on data
derived from the histologic type of tumor being
staged. However, the current AJCC staging system
for esophageal carcinoma is based primarily on
retrospective data from the Japanese Committee for
Registration of Oesophageal Carcinoma Cases,
which focused on patients with squamous cell carci-
noma of the cervical and thoracic esophagus.5, 6 The
adequacy of this system for esophageal carcinoma in
western Europe and North America is questionable
because most patients in western countries now have
adenocarcinoma of the distal esophagus and gastro-
esophageal junction. However, it seems appropriate
that adenocarcinomas of the gastroesophageal junc-
tion be staged along with tumors of the esophageal
body, because data from our institution and others
indicate that overall survival is not linked to tumor
histologic characteristics or location.7-9
The staging system must also reflect parameters
that have a strong prognostic influence for the
tumor being staged. Although the extent of tumor
invasion into the esophageal wall (T descriptor) as
currently described in the AJCC staging system
appears to be an important prognostic factor, the N
descriptors in this system are less specific and less
well validated. As a result, there is still controversy
regarding regional (N1) versus distant (M1) nodal
metastases. There is also no provision for the num-
ber of metastatic lymph nodes in the AJCC system,
a criterion reported to be important in predicting
survival.10-12
The designation of nonregional metastatic lymph
nodes as M1 disease again stems from the Japanese
data. The 5-year survival for 658 patients with
positive lymph nodes outside of the regional nodal
groups (M1) was only 5.2%, compared with 16.8%
for 1211 patients in whom only the regional nodes
were positive.5, 6 Little data exist in the western
literature concerning survival with respect to the
location of involved lymph nodes for patients with
resected esophageal carcinoma. Clark and associ-
ates13 reported on 43 patients with adenocarcinoma
of the distal esophagus and gastroesophageal junc-
tion. Lymph nodes were stratified into four groups
according to distance from the primary tumor. All
patients underwent en bloc esophagectomy with
radical lymphadenectomy. The location of involved
lymph nodes did not influence survival, but the
number of cases analyzed was small.
In accordance with the Japanese data, our study
suggests that in cases where the lymph nodes are
positive, the further the diseased lymph nodes are
from the primary tumor, the worse the prognosis.
However, even patients who had positive “N2”
nodes according to our revised staging system ap-
pear to have a better survival than do patients with
visceral metastases, who historically have a median
survival of 4 to 6 months.14 Our findings are in
agreement with those of Steup and colleagues,15
who studied 95 patients with carcinomas of the
gastroesophageal junction and determined that pa-
tients with lymph node metastasis outside the re-
Table IV. Median survival and hazard ratio (risk of




T0 N0, Tis N0, T1 N0 Not yet reached 0.10
T2 N0 M0 Not yet reached 0.20
T3 N0 M0 25 0.87
T1 N1 M0, T2 N1 M0 22.5 0.86
T3 N1 M0 18.8 1.00
T1 N2 M0, T2 N2 M0 13.9 2.09
T3 N2 M0 13.8 1.76
Any T4 6.5 6.63
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Fig. 3. A, Disease-free survival according to TNM stage. The revised staging system is noted in
parentheses. B, Disease-free survival according to the newly proposed stage groupings with the revised
TNM system. Table V describes stage groupings. Stage IV (T4, any N, M0 and any T, any N, M1) is not
depicted.
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Fig. 4. A, Overall survival according to number of positive lymph nodes. B, Overall survival curves of
patients with significantly different prognoses according to the number of positive lymph nodes.
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gional nodes had a better prognosis after resection
than did those with visceral M1 disease. As a result,
these authors also advocate the creation of an N2
category according to nodal location with respect to
the primary tumor site.
Both the number of positive lymph nodes and the
ratio of positive lymph nodes to total number of
nodes sampled are reported to influence survival
after resection of esophageal carcinomas.10-12 Skin-
ner and DeMeester10,12 incorporate an N2 category
into their WNM staging system; this represents
patients with more than four positive lymph nodes.
A previous report from this institution also suggests
that the number of diseased lymph nodes may
influence survival.9 In the current study, the number
of positive lymph nodes significantly influenced
prognosis when four or more nodes were involved
by metastatic disease. This finding needs further
validation in prospective studies, but it may be
useful as a stratification factor in future clinical
trials.
Other authors have suggested that the staging
system for esophageal carcinoma should be revised,
including Killinger and associates,16 who studied 345
patients undergoing resection of primary carcinoma
of the esophagus. Our data are similar to theirs in
the following respects. First, both studies report
similar 5-year survivals for patients with T1 N0 M0
and T2 N0 M0 disease, suggesting that these two
categories should be combined to form stage I.
Second, the survival of patients with T3 N0 M0
disease in both studies more closely parallels that of
patients with regional lymph node metastasis (N1).
Similarly, Ellis and colleagues17 reported on 265
patients who underwent resection for carcinoma of
the esophagus. Again, patients with T1 N0 M0
tumors had a similar survival to those with T2 N0
M0 lesions. Additionally, their data concur with
those of Skinner and coworkers8 and our own with
respect to the absolute number of positive lymph
nodes as an important prognostic indicator, suggest-
ing that this criterion should be used to stratify
patients in the N1 and N2 categories.
Although this study and those of the other au-
thors suggest that revision of the current AJCC
staging system for esophageal carcinoma is needed,
these data must be interpreted with caution for the
following reasons. First, in the ideal situation a
radical lymphadenectomy should be performed to
make nodal staging as accurate as possible. In this
study, although most patients underwent transtho-
racic esophagectomy with extensive nodal sampling,
systematic radical lymphadenectomies were not per-
formed and some positive lymph nodes may not
have been found. In the 21% of patients who had
transhiatal esophagectomies, lymph node sampling
was less extensive, with a greater potential for
missing involved nodes. Second, the nature of the
esophagectomy specimen can make pathologic eval-
uation and exact nodal location difficult. In some
cases the esophagus is resected with most nodal
tissue en bloc, leaving the classification of the lymph
nodes to the discretion of the pathologist, who has
never seen the specimen in situ. Also, the esophagus
shortens appreciably after resection, which may
confound nodal localization further.
Our experience suggests that it is appropriate to
formulate a new staging classification applicable to
both squamous cell and adenocarcinomas of the
esophagus and gastroesophageal junction that more
accurately reflects clinical outcome. Stage I would
include both T1 N0 M0 and T2 N0 M0 tumors.
Stage II would include disease limited to regional
lymph nodes (T1 through T3 N1 M0) and also T3
N0 M0 tumors. Stage III consists of all T1 through
T3 N2 M0 disease, reflecting the finding that pa-
tients with N2 disease, as defined here, have a worse
prognosis than that of those with N1 disease but
better than the historical outcome of patients with
visceral metastases (M1). Stage IV comprises all T4
lesions and also visceral metastases (M1). Table V
compares the proposed new system with the current
AJCC staging system. Stratification for the number
Table V. Current and proposed stage groupings for




Stage 0 T0 N0, Tis N0 M0 T0 N0, Tis N0 M0
Stage I T1 N0 M0 T1 N0 M0
T2 N0 M0
Stage II*
IIa T2 N0 M0 T3 N0 M0
T3 N0 M0 T1 N1 M0
IIb T1 N1 M0 T2 N1 M0
T2 N1 M0 T3 N1 M0
Stage III T3 N1 M0 T1 N2 M0
T4 any N M0 T2 N2 M0
T3 N2 M0
Stage IV Any T, any N, M1† T4 any N M0
Any T, any N, M1‡
*Subdivisions IIa and IIb are only applicable to the AJCC system.
†Represents both visceral and distant nodal metastases.
‡Represents visceral metastases only.
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of positive lymph nodes, especially if four or more
nodes are involved, appears to be important in
detecting patients with a significantly worse progno-
sis. Such a revision of the AJCC staging classifica-
tion will facilitate decisions about clinical care and
will enhance the ability to select patients for entry
into clinical trials for this difficult to treat malig-
nancy.
We thank Marie Gregorio, RN, and Jackie Hanson,
RN, for their invaluable assistance in collecting data on
patient follow-up, and Melody Owens for her outstanding
assistance in data management and manuscript prepara-
tion.
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Discussion
Dr. Tom R. DeMeester (Los Angeles, Calif.). The busi-
ness of staging esophageal carcinoma is certainly now
undergoing review. A number of articles have indicated
that at least the number of nodes involved is important
and has not previously been fully appreciated. This article
takes on particular emphasis in the era where the number
of adenocarcinoma associated with Barrett esophagus is
rising exponentially, as indicated in your presentation.
My questions focus on the alteration of the staging
methodology that you propose, namely whether survival is
affected by T1 and T2 tumors, the number of nodes
involved, and the location of the involved nodes. First,
your article and others preceding it all agree that the
number of nodes is important, that there is a difference
between having none, five or fewer, or more than five
nodes involved. What about the ratio of positive nodes to
negative nodes? There has been a discussion in the
literature that the ratio of involved to uninvolved removed
is important in prognosis; could you comment on this, or
do you have any data that would support or refute this
contention?
Dr. Korst. I do not have data pertaining to the number
of negative nodes.
Dr. DeMeester. My second question has to do with the
distance that a positive node is from the primary tumor
and its effect on survival. Is this really an important
phenomenon, or is it just that a patient who has distant
nodes involved is more likely to have a greater number of
nodes involved? In that regard, I wonder, did you have
situations where there were fewer than five nodes involved
but that they were some distance removed from the
primary tumor, that is, in the sites that you identified, with
a negative effect on prognosis?
Dr. Korst. There were situations where positive nodes
were found in distant nodal stations in the absence of
positive nodes immediately adjacent to the primary tu-
mor. In addition, there were situations where many posi-
tive nodes were found adjacent to the primary tumor, but
no distant nodes were positive. There thus did not seem to
be a correlation between the number of positive nodes
and the likelihood of distant nodal disease. Distance from
the primary tumor was an independent prognosticator in
the patients.
Dr. DeMeester. Did you say that a few positive nodes
but distantly removed correlated with survival?
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Dr. Korst. No.
Dr. DeMeester. So you do not think that the distance an
involved node is from the primary tumor is an indepen-
dent factor in prognosis?
Dr. Korst. No; I mean that I believe distance from the
primary tumor is an independent factor.
Dr. DeMeester. Do you know the number of nodes that
were removed per patient?
Dr. Korst. I do not have the figures concerning the total
number of lymph nodes removed. However, I can elabo-
rate a little bit on what is typically done during an
esophagectomy. As I said, most procedures were trans-
thoracic esophagectomies, and extensive mediastinal and
abdominal lymph node sampling was performed; however,
a radical, two-field or three-field lymphadenectomy is not
routinely done.
Dr. DeMeester. In that case, do you think that the data
you have are adequate for your analysis and recommen-
dations?
Dr. Korst. I think that the extensive node sampling that
was performed in those patients was adequate for the
drawing of some preliminary conclusions. However, I
agree that the more radical the lymphadenectomy, the
more accurate the staging will be.
Dr. DeMeester. My third question focuses on the re-
ports of histochemical studies done on lymph nodes, that
is, nodes that are normal by histologic examination but are
positive for metastatic tumor on histochemical analysis
with monoclonal antibody to identify epithelial cell rem-
nants. Some reports say that histochemically positive
nodes have an effect on survival. Could you comment on
whether these studies should be considered before we
begin to revamp our staging methodology of this disease?
Dr. Korst. If it affects survival, then perhaps it should be
considered as part of the staging process.
Dr. DeMeester. One area that I thought you may have
had the data to address but did not in the article or the
presentation is whether there is a difference in survival
between T1 and T2 tumors. For the sake of the audience,
I should define a T1 tumor. A T1 tumor is a tumor that
extends beyond the muscularis mucosa into the submu-
cosa.
Dr. Korst. Right.
Dr. DeMeester. And it differs from a T2 tumor in that a
T2 tumor extends into the muscularis propria. There has
been discussion that this difference is not of practical
significance; that is, they have a similar effect on survival.
Have you analyzed your specimens in an effort to identify
tumors that were limited by the muscularis mucosa, those
that extended into the submucosa, and those that ex-
tended into the muscularis propria?
Dr. Korst. Unfortunately, we didn’t break down the
tumors into mucosal versus submucosal, but obviously
that is a very heated area and it would be worth doing.
Dr. DeMeester. I think such information would be of
value, especially in the area of surveillance for early
disease.
My last question varies a bit from the staging, but of
course my interest was piqued by the fact that you had a
high local recurrence rate after your resections. In the
article, you reported a 45% to 50% local recurrence rate.
Do you think a more extensive esophagectomy and gas-
trectomy with an en bloc resection would have reduced
the local recurrence rate?
Dr. Korst. Of a total of 119 patients who had recurrent
disease, 22 had local recurrences and 53 had distant
metastatic disease. With this high rate of distant failure, it
intuitively seems unlikely that a more radical resection
would be of benefit.
Dr. James B. D. Mark (Stanford, Calif.). As you know,
there is a new proposed staging for lung cancer that
separates some node-positive from node-negative disease.
Right now in lung cancer, a single stage includes T3 N0
and T2 N2. You have again included in a single stage T3,
N0 and T1 through T2 N1. Do you think that you might
want to divide those into another stage, or a substage, so
that in the future you can separate all N0 cancers from any
with nodal involvement?
Dr. Korst. A close look at the slide with the survival
curves shows that with the exception of the group of
patients with T3 N0 tumors, the staging system broke
down so that N0 was stage I, N1 was stage II, and N2 was
stage III. If you look at the survival in the T3 N0 group,
there really was no difference between that group and the
rest of the patients with N1 disease. However, a significant
difference in survival is present between the T3 N0 group
and the rest of the N0 patients. It would be great if we
could group T3 N0 into stage I, because it would make it
even that much simpler, but the data do not allow us to do
that.
Dr. Mark. I could not process that entire multicolored
slide, but the one that followed it with the three lines I
could handle. In the middle one in was the N1. You know
what I am talking about?
Dr. Korst. Right. I know what you are talking about.
Dr. Mark. Second, you have accentuated the impor-
tance of numbers of nodes involved, yet nowhere in the
staging system is that taken into account. I realize that
this might be difficult, and Dr. DeMeester has ad-
dressed several questions about how many nodes you
removed and what percentage of nodes were removed
and so forth, but should that be an important part of the
staging system?
Dr. Korst. I think it should be. The problem with our
database is that some of those subgroups, specifically
those of more superficial tumors that are node positive, do
not have many patients in them. With the small number of
patients, it is difficult to make statistically valid compari-
sons with respect to number of nodes.
Dr. Mark. I just encourage you to be a little more
aggressive in operating on patients with cancer of the
esophagus. You are leaving too many not operated on, I
think.
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